[go: up one dir, main page]

SV1997000033A - Derivados de acido 4-arilbutirico sustituido como inhibisor de matriz de metaloproteasa - Google Patents

Derivados de acido 4-arilbutirico sustituido como inhibisor de matriz de metaloproteasa

Info

Publication number
SV1997000033A
SV1997000033A SV1997000033A SV1997000033A SV1997000033A SV 1997000033 A SV1997000033 A SV 1997000033A SV 1997000033 A SV1997000033 A SV 1997000033A SV 1997000033 A SV1997000033 A SV 1997000033A SV 1997000033 A SV1997000033 A SV 1997000033A
Authority
SV
El Salvador
Prior art keywords
metaloprotease
derivatives
acid substituted
arylbutyric acid
matrix inhibitor
Prior art date
Application number
SV1997000033A
Other languages
English (en)
Inventor
Harold C E Kluender
Brian R Dixon
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of SV1997000033A publication Critical patent/SV1997000033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS IHIBIDORES DE LA METALOPROTEASA DE MATRIZ, COMPOSICIONES FARMACEUTICA QUE LOS CONTIENEN Y UN PROCESO PARA USAR LOS MISMOS A FIN DE TRATAR UNA DIVERSIDAD DE TRASTORNOS FISIOLOGICOS, LOS COMPUESTOS DE LA PRESENTE INVENCION TIENEN LA FORMULA GENERALIZA I, ASI COMO SUS SALES FARMACEUTICAMENTE ACEPTABLES DE ESTOS MATERIALES.
SV1997000033A 1996-05-15 1997-05-12 Derivados de acido 4-arilbutirico sustituido como inhibisor de matriz de metaloproteasa SV1997000033A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64768296A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
SV1997000033A true SV1997000033A (es) 1999-01-14

Family

ID=24597888

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1997000033A SV1997000033A (es) 1996-05-15 1997-05-12 Derivados de acido 4-arilbutirico sustituido como inhibisor de matriz de metaloproteasa

Country Status (21)

Country Link
EP (1) EP0923529B1 (es)
JP (1) JP3354941B2 (es)
CN (1) CN1225620A (es)
AR (1) AR007101A1 (es)
AT (1) ATE205822T1 (es)
AU (1) AU727468B2 (es)
BR (1) BR9709075A (es)
CA (1) CA2253795C (es)
CO (1) CO5011113A1 (es)
DE (1) DE69706874T2 (es)
ES (1) ES2160955T3 (es)
HR (1) HRP970247B1 (es)
ID (1) ID17326A (es)
MY (1) MY116903A (es)
PA (1) PA8429501A1 (es)
SV (1) SV1997000033A (es)
TN (1) TNSN97086A1 (es)
TW (1) TW442468B (es)
WO (1) WO1997043237A1 (es)
YU (1) YU18897A (es)
ZA (1) ZA974033B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TNSN97084A1 (fr) 1996-05-15 2005-03-15 Bayer Corp Biaryl acetylenes comme inhibiteurs des matrices metalloproteinases
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
FR2832925B1 (fr) * 2001-12-03 2006-07-14 Lipha Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation
JP2012087113A (ja) * 2010-09-22 2012-05-10 Daicel Corp フェニル酢酸化合物
EP3126358A1 (de) * 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen
WO2015150363A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
CA2944617A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
WO2015150364A1 (de) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Substituierte benzotriazinonbutansäuren und ihre verwendung
US20170121315A1 (en) * 2014-06-12 2017-05-04 Bayer Pharma Aktiengesellschaft Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE650081A (es) * 1963-07-03
FR2378741A1 (fr) * 1977-02-01 1978-08-25 Fabre Sa Pierre Acides garyl goxo isovaleriques doues de proprietes antiphlogistiques et antalgiques
NZ323329A (en) 1995-12-22 1999-02-25 Warner Lambert Co 4-phenyl-piperidin-1-yl butyric acid derivatives and medicaments
HRP970242A2 (en) 1996-05-15 1998-04-30 Bayer Ag Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids

Also Published As

Publication number Publication date
ES2160955T3 (es) 2001-11-16
ATE205822T1 (de) 2001-10-15
MY116903A (en) 2004-04-30
CA2253795C (en) 2002-10-15
PA8429501A1 (es) 2000-05-24
EP0923529A1 (en) 1999-06-23
CA2253795A1 (en) 1997-11-20
TNSN97086A1 (fr) 2005-03-15
WO1997043237A1 (en) 1997-11-20
YU18897A (en) 1999-11-22
CO5011113A1 (es) 2001-02-28
DE69706874T2 (de) 2002-03-28
AU727468B2 (en) 2000-12-14
AR007101A1 (es) 1999-10-13
JPH11510518A (ja) 1999-09-14
HRP970247A2 (en) 1998-04-30
EP0923529B1 (en) 2001-09-19
BR9709075A (pt) 1999-08-03
DE69706874D1 (en) 2001-10-25
HRP970247B1 (en) 2002-02-28
ZA974033B (en) 1998-02-19
JP3354941B2 (ja) 2002-12-09
ID17326A (id) 1997-12-18
TW442468B (en) 2001-06-23
CN1225620A (zh) 1999-08-11
AU2938997A (en) 1997-12-05

Similar Documents

Publication Publication Date Title
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
UY26968A1 (es) Agentes terapéuticos
ES2128791T3 (es) Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos.
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
SV2002000232A (es) Derivados nuevos de benzoimidazole utiles como agentes antiproliferativos ref. pc 10608abcz/bb
PA8569201A1 (es) "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimimidazole derivatives as mek inhibitors"
ES2192588T3 (es) 4-(arilaminometilen)-2,4-dihidro-pirazol-3-onas.
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
DOP2003000613A (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole derivatives as mek inhibitors)
ES2161290T3 (es) Derivados de quinazolina.
AR001999A1 (es) Derivados de acido carboxilico y composiciones conteniendolos, utiles como inhibidores de metaloproteasa de matriz, y procesos para su preparacion.
AR027437A1 (es) Derivados de purina
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
CO4900036A1 (es) Compuestos inhibidores de metaloproteasas de amina ciclica substituida composiciones farmaceuticas que los contienen y metodos para su utilizacion
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
DOP2004000949A (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
NI200400073A (es) Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
SV1997000033A (es) Derivados de acido 4-arilbutirico sustituido como inhibisor de matriz de metaloproteasa
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
PA8444901A1 (es) Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios